Exsilio Therapeutics’ Post

Exciting December Ahead for Biotech Stocks Bluebird Bio and Structure Therapeutics! Biotech stocks Bluebird Bio (NASDAQ: BLUE) and Structure Therapeutics (NASDAQ: GPCR) are gearing up for a promising December with important events that could boost their stock prices. Stay tuned for potential milestones and market movements in the biotech sector! 📈💊 #BiotechStocks #BluebirdBio #StructureTherapeutics #StockMarket #InvestingOpportunities

All four #biotech IPOs this year have come from mid- to late-stage companies, but Metagenomi is looking to buck that trend. https://lnkd.in/dDiYmemp #biotechnology #geneediting #genetherapy #genetics #Metagenomi #pharmaceuticals

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

Gene&Cell Therapy >> Commit Biologics nabs Novo Holdings support in €16M seed round for complement platform: Novo Holdings is pitching in to Commit Biologics’ seed funding for its research on “supercharging” antibodies to turn on the complement system, an approach that could potentially lead to treatments for blood cancer and autoimmune diseases. The €16 million ($17 million) raise, led by Novo Holdings and Bioqube Ventures, will help accelerate development of Commit’s so-called Bispecific Complement Engaging (BiCE) platform. The funds should offer a runway through the start of 2026, Commit Biologics CEO Krishna Polu told Endpoints News in an interview. The complement system is part of the broader immune system that triggers an inflammatory response to pathogens. To activate the complement system in a targeted way, BiCE uses single domain antibodies that bind to the complement protein C1q. This approach could lead to killing cancer cells or immune cells that drive autoimmune disease, the Danish biotech said in a release. “We can basically take an antibody, use our technology to arm it with these complement activators, and essentially supercharge it,” Polu said, adding that the platform’s use of conventional antibodies could help derisk development. “Our goals under the seed financing are to arrive at two development candidates against two targets in different disease areas,” Polu said. One candidate will likely address a form of blood cancer, while the other may target CD19 for a B cell-mediated autoimmune disease, he added. Other companies are investigating CD19-targeting CAR-T therapies for autoimmune diseases such as systemic lupus erythematosus. But toxicity, manufacturing and cost hurdles mean these therapies may be limited to extremely sick patients, Polu said. “We think our platform can achieve a deep depletion of CD19-positive B cells in tissues, similar to CAR-Ts, but with certain advantages” such as fewer toxicities and manufacturing challenges, he added. Commit was founded in 2021 as a spinout from Denmark’s Aarhus University, and was initially supported and incubated by the BioInnovation Institute. Aarhus has been researching complement structural biology for around 30 years. #lucidquest #genetherapy #celltherapy

CRISPR Market | Grows at CAGR of 15.6% by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/d7U9K7QR The global CRISPR market in terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028. Intellia Therapeutics, Inc. Editas Medicine Verve Therapeutics Beam Therapeutics Locus Biosciences, Inc. Synthego Corporation Metagenomi Caribou Biosciences eGenesis, Inc. Poseida Therapeutics, Inc. Mammoth Biosciences Aelian Biotechnology SNIPR Biome - A CRISPR Company Hudson River Biotechnology Caspr Biotech CRISPR Therapeutics Scribe Therapeutics Cardea Bio (part of Paragraf®) CyGenica Chroma Medicine Ceptur Therapeutics Affini-T Therapeutics CG Oncology ArriVent Biopharma Precision Fermentation, Inc. Forge Biologics Orna Therapeutics Antios Therapeutics Inflammatix, Inc. Cellarity Maze Therapeutics

Gene&Cell Therapy >> SK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva: Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. SK Bioscience now has a 60% stake in the CDMO IDT Biologika after signing a deal with German pharma company Klocke, in a deal worth 339 billion Korean won ($244 million). Klocke will retain a 40% share in the CDMO, according to a Thursday release. Lonza’s former CEO Pierre-Alain Ruffieux is joining Cytiva as its new chief operating officer effective July, according to a Thursday release. This is a newly created role for Ruffieux, who left Lonza in September 2023. Ruffieux will be responsible for improving the customer experience and engagement at Cytiva. “[Ruffieux] brings unparalleled experience and a deep understanding of how suppliers positively impact the success of our pharmaceutical and biotechnology customers,” Cytiva’s CEO Chris Riley told Endpoints News in a statement. Evotec subsidiary, Just – Evotec Biologics, was chosen by the US Department of Defense for a multi-year project worth $39 million to develop monoclonal antibody technologies. The company will focus on decreasing the time it takes to develop and manufacture monoclonal antibodies so they can enter the clinic sooner, according to a Wednesday release. API manufacturer Veranova is investing $30 million to expand its antibody-drug conjugate facility in Devens, MA. The expansion will include a new process development lab as well as two new manufacturing suites, according to the company Thursday. ProBio opened its new plasmid DNA and viral vector manufacturing facility in Hopewell, NJ, on Tuesday. The 128,000 square-foot site will add to the company’s cell and gene therapy capabilities. Glenmark Pharmaceuticals is recalling 114 batches of 750 mg potassium chloride extended-release capsules because of “failed dissolution.” The capsules are for patients with low potassium in the blood. The production issue could cause hyperkalemia and cardiac arrest, according to a release Tuesday. Gilead’s Kite is testing Cellares’ automated cell therapy platform, dubbed the Cell Shuttle, in a proof of concept study, the companies said Thursday. Bristol Myers Squibb, Cabaletta and Lyell Immunopharma have also tapped Cellares for its automated tech. Charles River Laboratories has partnered with the Gates Institute at the University of Colorado Anschutz Medical Campus to make lentiviral vectors for the institute’s use for CAR-T cell therapies in blood cancers, according to a Tuesday release. Generic and biosimilar manufacturer Boston Oncology Arabia received a $35 million investment from investment firm TVM Capital Healthcare. The funding will be for the manufacturer to reach full formulation and fill-finish manufacturing at its site… #lucidquest #genetherapy #celltherapy

𝐎𝐫𝐮𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 $𝟏 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐋𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐃𝐞𝐚𝐥 𝐰𝐢𝐭𝐡 𝐕𝐞𝐫𝐭𝐞𝐱 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 Orum Therapeutics Orum Therapeutics, a clinical-stage biotech company pioneering degrader-antibody conjugates (DACs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals (Nasdaq: VRTX) Vertex Pharmaceuticals. This agreement grants Vertex rights to use Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology for discovering novel targeted conditioning agents for gene editing. Vertex will have the option to obtain a worldwide, exclusive license to research, develop, manufacture, and commercialize DACs using Orum’s TPD² technology. Orum will receive an upfront payment of $15 million and is eligible for additional option payments and milestones of up to $310 million per target for up to three targets, plus tiered royalties on future global sales. Vertex will handle all research, development, and commercialization efforts. "Vertex, a leader in innovative medicines and the first to receive FDA approval for a CRISPR/Cas9 gene-edited therapy, has chosen Orum’s TPD² technology to discover novel targeted conditioning agents," said Sung Joo Lee, Ph.D. SJ Lee, CEO and founder of Orum Therapeutics. "This agreement offers potential treatments for patients in a novel indication space with our leading targeted protein degradation approach." #Biotech #ProteinDegradation #GeneEditing #DACs #InnovativeMedicine #HealthcareInnovation #VertexPharmaceuticals #OrumTherapeutics #ClinicalTrials

OCYONBIO Presents at Biomap Consortium Industry Day April 5-2024 Excited to share insights from our recent presentation at the BioMaP Consortium Industry Day held at the Strategic Analysis Executive Conference Center in Arlington, VA. OcyonBio has demonstrated its dedication to shaping the biomanufacturing landscape through innovation and strategic partnerships. 🔬 Company Mission At OcyonBio, we're not just about developing cutting-edge technology; we're making life-saving therapies accessible. Our 200,000 sq. ft facility is equipped with the latest in R&D suites, gene therapy capabilities, and continuous manufacturing processes essential for the next generation of therapeutics. 💡 Capabilities Spotlight We're at the forefront of biologics, with competencies spanning from bacterial and mammalian drug substances to vials and cartridges for drug products. Our expertise in cell and gene therapy is marked by our advanced viral vector manufacturing and clinical-scale solid dosage capabilities, including direct compression and granulation. 🤝 Building Partnerships The BioMaP Consortium Industry Day was an excellent platform for us to showcase our commitment to fostering collaborations that drive innovation. By connecting with government entities and other industry leaders, we've reinforced our goal to expand the biopharmaceutical manufacturing sector's capabilities. 🚀 Future-Forward Approach Our presentation highlighted how OcyonBio's expansion into sterile manufacturing, supported by our partnership with Marchessini, bolsters our mission to be at the forefront of the industry. This expansion is a testament to our ability to meet the dynamic needs of the market and deliver quality, efficiency, and innovation. We are proud to be part of a consortium that's dedicated to preparedness and response for public health emergencies. By advancing biomanufacturing technologies, we ensure a resilient future for the healthcare sector. 🔗 For more on our capabilities and offerings, visit OcyonBio.com. Join the conversation on how we can further innovate and collaborate within the biopharmaceutical manufacturing industry! #OcyonBio #BioMaPConsortium #Biomanufacturing #PublicHealth #Innovation #Partnership #GeneTherapy #BARDA

Recent advancements in #Cell and #gene therapies, #RNA therapeutics, and complex biologics offer unprecedented opportunities to treat complex diseases. However, traditional early discovery research spaces and large-scale manufacturing models are outdated. This necessitates new, integrated offerings like the ones we have at SmartLabs which combine reconfigurable lab infrastructure, operations, and scientific expertise to meet the modern demands of science. Our CEO @BrianTaylor recently spoke with BioPharma Dive on the ways in which these offerings are benefitting companies from small start-ups to established organizations as well as his vision for how to future-proof in an ever-changing industry. Read the full Q&A on BioPharma Dive: https://hubs.ly/Q02zkNX10 #Biopharma #HemophiliaB #DrugDevelopment #ClinicalTrials #DrugManufacturing #ClinicalData #BusinessDevelopment #Biopharma #DrugDiscovery #IND #FDA

Thoughts on this? >> Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #competitivemarketing